DOCSLIB.ORG

EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production This information is current as Muyao Guo, Madeline J. Price, Dillon G. Patterson, of September 28, 2021. Benjamin G. Barwick, Robert R. Haines, Anna K. Kania, John E. Bradley, Troy D. Randall, Jeremy M. Boss and Christopher D. Scharer J Immunol published online 29 December 2017 http://www.jimmunol.org/content/early/2017/12/29/jimmun Downloaded from ol.1701470 Supplementary http://www.jimmunol.org/content/suppl/2017/12/29/jimmunol.170147 Material 0.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published December 29, 2017, doi:10.4049/jimmunol.1701470 The Journal of Immunology EZH2 Represses the B Cell Transcriptional Program and Regulates Antibody-Secreting Cell Metabolism and Antibody Production Muyao Guo,*,† Madeline J. Price,* Dillon G. Patterson,* Benjamin G. Barwick,‡ Robert R. Haines,* Anna K. Kania,* John E. Bradley,x Troy D. Randall,x Jeremy M. Boss,* and Christopher D. Scharer* Epigenetic remodeling is required during B cell differentiation. However, little is known about the direct functions of epigenetic enzymes in Ab-secreting cells (ASC) in vivo. In this study, we examined ASC differentiation independent of T cell help and germinal center reactions using mice with inducible or B cell–specific deletions of Ezh2. Following stimulation with influenza virus or LPS, Ezh2-deficient ASC poorly proliferated and inappropriately maintained expression of inflammatory pathways, B cell–lineage Downloaded from transcription factors, and Blimp-1–repressed genes, leading to fewer and less functional ASC. In the absence of EZH2, genes that normally gained histone H3 lysine 27 trimethylation were dysregulated and exhibited increased chromatin accessibility. Furthermore, EZH2 was also required for maximal Ab secretion by ASC, in part due to reduced mitochondrial respiration, impaired glucose metabolism, and poor expression of the unfolded-protein response pathway. Together, these data demonstrate that EZH2 is essential in facilitating epigenetic changes that regulate ASC fate, function, and metabolism. The Journal of Immunology, 2018, 200: 000–000. http://www.jimmunol.org/ he humoral immune response is initiated when B cells are enhanced metabolism and Ab secretion (1–3). The ASC tran- stimulated to differentiate into Ab-secreting cells (ASC), scriptional program is enabled by the expression of transcription T also known as plasma cells. Irrespective of how they are factors—such as Blimp-1, XBP1, and IRF4, which reinforce and activated or the availability of T cell help, a distinct set of support ASC transcriptional changes (2, 4)—that are coupled to a reprogramming events are required to terminate the B cell–fate reorganization of the epigenome (5–7). Although the transcription program and initiate a new gene expression program that supports factors and genes they regulate have been studied biochemically and genetically, little is known about the role of epigenetic by guest on September 28, 2021 modifiers in ASC function and programming. *Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322; †Xiangya School of Medicine, Central South University, Changsha, 410008, China; Epigenetic modifications are dynamic during distinct stages of ‡Department of Radiation Oncology, Emory University, Atlanta, GA 30322; and xDivision B cell differentiation. In both mice and humans, DNA methylation of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama is primarily lost as B cells differentiate to ASC in response to both at Birmingham, Birmingham, AL 35294 T cell–dependent and –independent stimuli (8–10). Deletion of the ORCIDs: 0000-0003-1347-0848 (M.G.); 0000-0001-6053-5216 (D.G.P.); 0000-0002- 5819-5694 (A.K.K.); 0000-0002-2432-1840 (J.M.B.); 0000-0001-7716-8504 (C.D.S.). maintenance methyltransferase Dnmt1 leads to a reduction in germinal center (GC) B cells (11), but whether de novo DNA Received for publication October 23, 2017. Accepted for publication November 29, 2017. methylation is required for B cell differentiation is not known. This work was supported by National Institutes of Health Grants 1R01AI123733 Histone modifications, characterized by chromatin immunopre- to J.M.B.; P01 AI 125180-02 to J.M.B. and T.D.R.; T32 GM0008490 to R.R.H., cipitation (ChIP) sequencing (ChIP-seq), have cell type–specific A.K.K., and B.G.B.; F31 AI112261 to B.G.B.; and F31 1F31 AI131532 to R.R.H. patterns in naive B cells (nB), ex vivo–differentiated ASC, and in The sequencing data presented in this article have been submitted to the National GC B cells (12–16). However, few studies have examined the role Center for Biotechnology Information’s Gene Expression Omnibus (https://www. ncbi.nlm.nih.gov/geo/) under accession number GSE103195. of histone-modifying enzymes using genetic approaches (5). Address correspondence and reprint requests to Dr. Christopher D. Scharer and Deletion of the histone acetyltransferase, MOZ, reduces GC Prof. Jeremy M. Boss, Emory University, 1510 Clifton Road, Atlanta, GA 30322. B cells and skews responding B cells toward low-affinity IgM+ E-mail addresses: [email protected] (C.D.S.) and [email protected] (J.M.B.) memory B cells (17). Additionally, treatment of mice with histone The online version of this article contains supplemental material. deacetylase inhibitors reduces B cell responses (18), indicating Abbreviations used in this article: actB, activated B cell; AID, activation-induced that both erasing and writing de novo epigenetic modifications is cytidine deaminase; ASC, Ab-secreting cell; ATAC-seq, assay for transposase- accessible chromatin sequencing; CD19-Ezh2KO, Ezh2fl/flCD19Cre/+; ChIP, chroma- an essential process in B cell differentiation. Importantly, epi- tin immunoprecipitation; ChIP-seq, ChIP sequencing; Ctl, control; CTV, CellTrace genetic modifiers are frequent targets of both activating and Violet; DAR, differentially accessible region; DEG, differentially expressed gene; inactivating mutations in lymphomas (19, 20). Therefore, a full ERT2-Cre Ctl, Ezh2fl/+Rosa26CreERT2/+;ERT2-Ezh2KO, Ezh2fl/flRosa26CreERT2/+; EZH2, enhancer of zest 2; FC, fold change; FDR, false discovery rate; FSC, forward understanding of epigenetic mechanisms and targets for distinct light scatter; GC, germinal center; GSEA, gene set enrichment analysis; HA, hem- enzymes is important to manipulate B cell differentiation and to agglutinin; H3K27me3, histone H3 lysine 27 trimethylation; KO, knockout; MEDS, mosaic end double stranded; nB, naive B cell; PC, principal component; PR8, A/PR8/ understand the effects of therapeutics targeting these enzymes. 34 strain of influenza; PRC2, polycomb repressive complex 2; qPCR, quantitative One of the best characterized repressive epigenetic histone PCR; rppm, reads per peak per million; RT-qPCR, quantitative RT-PCR; SSC, side modifications is the trimethylation of histone H3 at lysine scatter; UPR, unfolded-protein response. 27 (H3K27me3), which is mediated by the polycomb repressive Copyright Ó 2017 by The American Association of Immunologists, Inc. 0022-1767/17/$35.00 complex 2 (PRC2) (21, 22). Enhancer of zest 2 (EZH2) is the www.jimmunol.org/cgi/doi/10.4049/jimmunol.1701470 2 EZH2 IN ASC FUNCTION catalytic subunit of the PRC2 complex and functions as an essential were enriched by positive selection of CD138+ cells from the spleens of transcriptional silencer (23–25). EZH2 is upregulated in pre–B cells, mice 3 d post–LPS inoculation. Splenocytes were first stained with CD138- in which it is necessary for VDJ recombination during B cell de- allophycocyanin (14205, clone 281-2; BioLegend) and immunomagnetic enrich- k ment was performed using anti-allophycocyanin microbeads (130-090-855; velopment (26) and to repress germline Ig transcription (27). EZH2 Miltenyi Biotec). Enriched populations were analyzed for purity by flow is expressed at low levels in quiescent, nB, but is highly upregulated cytometry (Supplemental Fig. 1A, 1B). For FACS sorting of cellular division in GC B cells where it facilitates cellular proliferation, protects from samples in Fig. 1: following 3 d LPS inoculation, adoptively transferred activation-induced cytidine deaminase (AID) off-target activity, and CD45.1 cells were stained with CD45.1-PE (12-0453-82, clone A20; Bio- science) and immunomagnetic enrichment was performed using anti-PE represses the differentiation of GC B cells into ASC (15, 16, 28, 29). microbeads (130-048-801; Miltenyi Biotec) prior to FACS sorting as previ- EZH2 interacts with distinct sets of transcription factors, such as ously described (8). BCL6inGCBcells(29)andBlimp-1inASC(30),todirectcell
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Clinical Utility of Recently Identified Diagnostic, Prognostic, And
    Modern Pathology (2017) 30, 1338–1366 1338 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms Arantza Onaindia1, L Jeffrey Medeiros2 and Keyur P Patel2 1Instituto de Investigacion Marques de Valdecilla (IDIVAL)/Hospital Universitario Marques de Valdecilla, Santander, Spain and 2Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA Genomic profiling studies have provided new insights into the pathogenesis of mature B-cell neoplasms and have identified markers with prognostic impact. Recurrent mutations in tumor-suppressor genes (TP53, BIRC3, ATM), and common signaling pathways, such as the B-cell receptor (CD79A, CD79B, CARD11, TCF3, ID3), Toll- like receptor (MYD88), NOTCH (NOTCH1/2), nuclear factor-κB, and mitogen activated kinase signaling, have been identified in B-cell neoplasms. Chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, Waldenström macroglobulinemia, hairy cell leukemia, and marginal zone lymphomas of splenic, nodal, and extranodal types represent examples of B-cell neoplasms in which novel molecular biomarkers have been discovered in recent years. In addition, ongoing retrospective correlative and prospective outcome studies have resulted in an enhanced understanding of the clinical utility of novel biomarkers. This progress is reflected in the 2016 update of the World Health Organization classification of lymphoid neoplasms, which lists as many as 41 mature B-cell neoplasms (including provisional categories). Consequently, molecular genetic studies are increasingly being applied for the clinical workup of many of these neoplasms. In this review, we focus on the diagnostic, prognostic, and/or therapeutic utility of molecular biomarkers in mature B-cell neoplasms.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Quantigene Flowrna Probe Sets Currently Available
    QuantiGene FlowRNA Probe Sets Currently Available Accession No. Species Symbol Gene Name Catalog No. NM_003452 Human ZNF189 zinc finger protein 189 VA1-10009 NM_000057 Human BLM Bloom syndrome VA1-10010 NM_005269 Human GLI glioma-associated oncogene homolog (zinc finger protein) VA1-10011 NM_002614 Human PDZK1 PDZ domain containing 1 VA1-10015 NM_003225 Human TFF1 Trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) VA1-10016 NM_002276 Human KRT19 keratin 19 VA1-10022 NM_002659 Human PLAUR plasminogen activator, urokinase receptor VA1-10025 NM_017669 Human ERCC6L excision repair cross-complementing rodent repair deficiency, complementation group 6-like VA1-10029 NM_017699 Human SIDT1 SID1 transmembrane family, member 1 VA1-10032 NM_000077 Human CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) VA1-10040 NM_003150 Human STAT3 signal transducer and activator of transcripton 3 (acute-phase response factor) VA1-10046 NM_004707 Human ATG12 ATG12 autophagy related 12 homolog (S. cerevisiae) VA1-10047 NM_000737 Human CGB chorionic gonadotropin, beta polypeptide VA1-10048 NM_001017420 Human ESCO2 establishment of cohesion 1 homolog 2 (S. cerevisiae) VA1-10050 NM_197978 Human HEMGN hemogen VA1-10051 NM_001738 Human CA1 Carbonic anhydrase I VA1-10052 NM_000184 Human HBG2 Hemoglobin, gamma G VA1-10053 NM_005330 Human HBE1 Hemoglobin, epsilon 1 VA1-10054 NR_003367 Human PVT1 Pvt1 oncogene homolog (mouse) VA1-10061 NM_000454 Human SOD1 Superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))
    [Show full text]
  • Thymocyte Development Gene That Regulates Double-Negative
    Expression Profiling of Immature Thymocytes Revealed a Novel Homeobox Gene That Regulates Double-Negative Thymocyte Development This information is current as of September 26, 2021. Masahito Kawazu, Go Yamamoto, Mayumi Yoshimi, Kazuki Yamamoto, Takashi Asai, Motoshi Ichikawa, Sachiko Seo, Masahiro Nakagawa, Shigeru Chiba, Mineo Kurokawa and Seishi Ogawa J Immunol 2007; 179:5335-5345; ; Downloaded from doi: 10.4049/jimmunol.179.8.5335 http://www.jimmunol.org/content/179/8/5335 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2008/03/12/179.8.5335.DC1 Material References This article cites 49 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/179/8/5335.full#ref-list-1 Why The JI? Submit online. by guest on September 26, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights
    [Show full text]
  • Xo GENE PANEL
    xO GENE PANEL Targeted panel of 1714 genes | Tumor DNA Coverage: 500x | RNA reads: 50 million Onco-seq panel includes clinically relevant genes and a wide array of biologically relevant genes Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4
    [Show full text]
  • Supplementary Table 5. Clover Results Indicate the Number Of
    Supplementary Table 5. Clover results indicate the number of chromosomes with transcription factor binding motifs statistically over‐ or under‐represented in HTE DHS within intergenic sequence (more than 2kb outside of any gene). Analysis was divided into three groups (all DHS, HTE‐selective DHS, and ubiquitous DHS). Motifs with more than one entry in the databases utilized were edited to retain only the first occurrence of the motif. All DHS x Intergenic TE­selective DHS x Intergenic Ubiquitous DHS x Intergenic ID Name p < 0.01 p > 0.99 ID Name p < 0.01 p > 0.99 ID Name p < 0.01 p > 0.99 MA0002.2 RUNX1 23 0 MA0080.2 SPI1 23 0 MA0055.1 Myf 23 0 MA0003.1 TFAP2A 23 0 MA0089.1 NFE2L1::MafG 23 0 MA0068.1 Pax4 23 0 MA0039.2 Klf4 23 0 MA0098.1 ETS1 23 0 MA0080.2 SPI1 23 0 MA0055.1 Myf 23 0 MA0099.2 AP1 23 0 MA0098.1 ETS1 23 0 MA0056.1 MZF1_1‐4 23 0 MA0136.1 ELF5 23 0 MA0139.1 CTCF 23 0 MA0079.2 SP1 23 0 MA0145.1 Tcfcp2l1 23 0 V$ALX3_01 ALX‐3 23 0 MA0080.2 SPI1 23 0 MA0150.1 NFE2L2 23 0 V$ALX4_02 Alx‐4 23 0 myocyte enhancer MA0081.1 SPIB 23 0 MA0156.1 FEV 23 0 V$AMEF2_Q6 factor 23 0 MA0089.1 NFE2L1::MafG 23 0 V$AP1FJ_Q2 activator protein 1 23 0 V$AP1_01 AP‐1 23 0 MA0090.1 TEAD1 23 0 V$AP4_Q5 activator protein 4 23 0 V$AP2_Q6_01 AP‐2 23 0 MA0098.1 ETS1 23 0 V$AR_Q6 half‐site matrix 23 0 V$ARX_01 Arx 23 0 BTB and CNC homolog MA0099.2 AP1 23 0 V$BACH1_01 1 23 0 V$BARHL1_01 Barhl‐1 23 0 BTB and CNC homolog MA0136.1 ELF5 23 0 V$BACH2_01 2 23 0 V$BARHL2_01 Barhl2 23 0 MA0139.1 CTCF 23 0 V$CMAF_02 C‐MAF 23 0 V$BARX1_01 Barx1 23 0 MA0144.1 Stat3 23 0
    [Show full text]
  • Functional Annotation of Human Long Noncoding Rnas Using Chromatin
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.13.426305; this version posted January 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Funconal annotaon of human long noncoding RNAs using chroman conformaon data Saumya Agrawal1, Tanvir Alam2, Masaru Koido1,3, Ivan V. Kulakovskiy4,5, Jessica Severin1, Imad ABugessaisa1, Andrey Buyan5,6, Josee Dos&e7, Masayoshi Itoh1,8, Naoto Kondo9, Yunjing Li10, Mickaël Mendez11, Jordan A. Ramilowski1,12, Ken Yagi1, Kayoko Yasuzawa1, CHi Wai Yip1, Yasushi Okazaki1, MicHael M. Ho9man11,13,14,15, Lisa Strug10, CHung CHau Hon1, CHikashi Terao1, Takeya Kasukawa1, Vsevolod J. Makeev4,16, Jay W. SHin1, Piero Carninci1, MicHiel JL de Hoon1 1RIKEN Center for Integra&ve Medical Sciences, YokoHama, Japan. 2College of Science and Engineering, Hamad Bin KHalifa University, DoHa, Qatar. 3Ins&tute of Medical Science, THe University of Tokyo, Tokyo, Japan. 4Vavilov Ins&tute of General Gene&cs, Russian Academy of Sciences, Moscow, Russia. 5Ins&tute of Protein ResearcH, Russian Academy of Sciences, PusHcHino, Russia. 6Faculty of Bioengineering and Bioinforma&cs, Lomonosov Moscow State University, Moscow, Russia. 7Department of BiocHemistry, Rosalind and Morris Goodman Cancer ResearcH Center, McGill University, Montréal, QuéBec, Canada. 8RIKEN Preven&ve Medicine and Diagnosis Innova&on Program, Wako, Japan. 9RIKEN Center for Life Science TecHnologies, YokoHama, Japan. 10Division of Biosta&s&cs, Dalla Lana ScHool of PuBlic HealtH, University of Toronto, Toronto, Ontario, Canada. 11Department of Computer Science, University of Toronto, Toronto, Ontario, Canada. 12Advanced Medical ResearcH Center, YokoHama City University, YokoHama, Japan.
    [Show full text]
  • Batf3 and Id2 Have a Synergistic Effect on Irf8-Directed Classical Cd8α+ Dendritic Cell Development
    Batf3 and Id2 Have a Synergistic Effect on Irf8-Directed Classical CD8α+ Dendritic Cell Development This information is current as Hemant Jaiswal, Monika Kaushik, Rachid Sougrat, Monica of October 3, 2021. Gupta, Anup Dey, Rohit Verma, Keiko Ozato and Prafullakumar Tailor J Immunol 2013; 191:5993-6001; Prepublished online 13 November 2013; doi: 10.4049/jimmunol.1203541 http://www.jimmunol.org/content/191/12/5993 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/11/13/jimmunol.120354 Material 1.DC1 http://www.jimmunol.org/ References This article cites 57 articles, 38 of which you can access for free at: http://www.jimmunol.org/content/191/12/5993.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 3, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Batf3 and Id2 Have a Synergistic Effect on Irf8-Directed Classical CD8a+ Dendritic Cell Development Hemant Jaiswal,* Monika Kaushik,* Rachid Sougrat,† Monica Gupta,‡ Anup Dey,‡ Rohit Verma,* Keiko Ozato,‡ and Prafullakumar Tailor* Dendritic cells (DCs) are heterogeneous cell populations represented by different subtypes, each varying in terms of gene expression patterns and specific functions.
    [Show full text]
  • Supplementary Table 4. Clover Results Indicate The
    Supplementary Table 4. Clover results indicate the number of chromosomes that returned transcription factor binding motifs as statistically over‐ or under‐represented in HTE DHS overlapping promoters. Analysis was divided into three groups (all DHS, HTE‐selective DHS, and ubiquitous DHS). Motifs with more than one entry in the databases were edited to include only the first occurrence of the motif . All DHS x 2kbUp TE­selective DHS x 2kbUp Ubiquitous DHS x 2kbUp ID Name p < 0.01 p > 0.99 ID Name p < 0.01 p > 0.99 ID Name p < 0.01 p > 0.99 MA0028.1 ELK1 23 0 V$FRA1_Q5 FRA1 16 0 MA0027.1 En1 23 0 MA0039.2 Klf4 23 0 V$AP1_Q4_01 AP‐1 15 0 MA0028.1 ELK1 23 0 MA0060.1 NFYA 23 0 V$AP1FJ_Q2 activator protein 1 10 0 MA0039.2 Klf4 23 0 BTB and CNC MA0062.2 GABPA 23 0 V$BACH1_01 homolog 1 9 0 MA0060.1 NFYA 23 0 MA0068.1 Pax4 23 0 V$MAFB_01 MAFB 9 0 MA0062.2 GABPA 23 0 MA0076.1 ELK4 23 0 V$NFE2_01 NF‐E2 p45 9 0 MA0063.1 Nkx2‐5 23 0 MA0079.2 SP1 23 0 V$CMAF_02 C‐MAF 8 0 MA0068.1 Pax4 23 0 BTB and CNC MA0080.2 SPI1 23 0 V$BACH2_01 homolog 2 7 0 MA0076.1 ELK4 23 0 MA0081.1 SPIB 23 0 V$HEB_Q6 HEB 7 0 MA0079.2 SP1 23 0 MA0098.1 ETS1 23 0 V$P53_05 p53 7 0 MA0080.2 SPI1 23 0 MA0108.2 TBP 23 0 V$P63_01 p63 7 0 MA0081.1 SPIB 23 0 MA0113.1 NR3C1 23 0 V$MAF_Q6_01 MAF 6 0 MA0084.1 SRY 23 0 MA0136.1 ELF5 23 0 V$AP4_Q6 activator protein 4 5 0 MA0098.1 ETS1 23 0 V$ALX3_01 ALX‐3 23 0 V$ELF1_Q5 ELF1 5 0 MA0108.2 TBP 23 0 V$ALX4_02 Alx‐4 23 0 V$ETS_Q4 Ets 5 0 MA0113.1 NR3C1 23 0 myocyte enhancer V$AMEF2_Q6 factor 23 0 V$GABPALPHA_Q4 GABP‐alpha 5 0 MA0151.1 ARID3A 23
    [Show full text]
  • Table SII. Significantly Differentially Expressed Mrnas of GSE23558 Data Series with the Criteria of Adjusted P<0.05 And
    Table SII. Significantly differentially expressed mRNAs of GSE23558 data series with the criteria of adjusted P<0.05 and logFC>1.5. Probe ID Adjusted P-value logFC Gene symbol Gene title A_23_P157793 1.52x10-5 6.91 CA9 carbonic anhydrase 9 A_23_P161698 1.14x10-4 5.86 MMP3 matrix metallopeptidase 3 A_23_P25150 1.49x10-9 5.67 HOXC9 homeobox C9 A_23_P13094 3.26x10-4 5.56 MMP10 matrix metallopeptidase 10 A_23_P48570 2.36x10-5 5.48 DHRS2 dehydrogenase A_23_P125278 3.03x10-3 5.40 CXCL11 C-X-C motif chemokine ligand 11 A_23_P321501 1.63x10-5 5.38 DHRS2 dehydrogenase A_23_P431388 2.27x10-6 5.33 SPOCD1 SPOC domain containing 1 A_24_P20607 5.13x10-4 5.32 CXCL11 C-X-C motif chemokine ligand 11 A_24_P11061 3.70x10-3 5.30 CSAG1 chondrosarcoma associated gene 1 A_23_P87700 1.03x10-4 5.25 MFAP5 microfibrillar associated protein 5 A_23_P150979 1.81x10-2 5.25 MUCL1 mucin like 1 A_23_P1691 2.71x10-8 5.12 MMP1 matrix metallopeptidase 1 A_23_P350005 2.53x10-4 5.12 TRIML2 tripartite motif family like 2 A_24_P303091 1.23x10-3 4.99 CXCL10 C-X-C motif chemokine ligand 10 A_24_P923612 1.60x10-5 4.95 PTHLH parathyroid hormone like hormone A_23_P7313 6.03x10-5 4.94 SPP1 secreted phosphoprotein 1 A_23_P122924 2.45x10-8 4.93 INHBA inhibin A subunit A_32_P155460 6.56x10-3 4.91 PICSAR P38 inhibited cutaneous squamous cell carcinoma associated lincRNA A_24_P686965 8.75x10-7 4.82 SH2D5 SH2 domain containing 5 A_23_P105475 7.74x10-3 4.70 SLCO1B3 solute carrier organic anion transporter family member 1B3 A_24_P85099 4.82x10-5 4.67 HMGA2 high mobility group AT-hook 2 A_24_P101651
    [Show full text]